Advertisement
Advertisement

BEAM

BEAM logo

Beam Therapeutics Inc. Common Stock

27.60
USD
Sponsored
-1.69
-5.76%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

27.71

+0.11
+0.39%

BEAM Earnings Reports

Positive Surprise Ratio

BEAM beat 14 of 24 last estimates.

58%

Next Report

Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$13.04M
/
-$0.99
Implied change from Q3 25 (Revenue/ EPS)
+34.42%
/
-10.00%
Implied change from Q4 24 (Revenue/ EPS)
-56.64%
/
-9.17%

Beam Therapeutics Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, BEAM reported earnings of -1.10 USD per share (EPS) for Q3 25, missing the estimate of -1.06 USD, resulting in a -3.72% surprise. Revenue reached 9.70 million, compared to an expected 12.66 million, with a -23.41% difference. The market reacted with a -6.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.99 USD, with revenue projected to reach 13.04 million USD, implying an decrease of -10.00% EPS, and increase of 34.42% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Beam Therapeutics Inc. Common Stock reported EPS of -$1.10, missing estimates by -3.72%, and revenue of $9.70M, -23.41% below expectations.
The stock price moved down -6.23%, changed from $24.25 before the earnings release to $22.74 the day after.
The next earning report is scheduled for Feb 23, 2026.
Based on 16 analysts, Beam Therapeutics Inc. Common Stock is expected to report EPS of -$0.99 and revenue of $13.04M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement